D
Neurogene Inc. NGNE
$15.43 -$0.0783-0.51% NASDAQ
Recommendation
Prev Close
$15.51
Volume
21,914
Avg Vol (90D)
264,014
Market Cap
$221.20M
Dividend & Yield
--
52-Week Range
$6.88 - $74.49
P/E (TTM)
--
EPS (TTM)
-$4.37
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Neurogene (NASDAQ:NGNE) Given New $45.00 Price Target at HC Wainwright
5/13/2025 - Ticker Report
Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted NGNE Stock News
5/13/2025 - GuruFocus
Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained NGNE Stock News
5/13/2025 - GuruFocus
Neurogene price target lowered by $5 at H.C. Wainwright, here's why
5/13/2025 - The Fly
Neurogene (NGNE, $17.7) price may drop as it broke higher Bollinger Band on May 12, 2025
5/13/2025 - Tickeron - Stocks
Neurogene (NGNE, $17.7) entered Uptrend as Momentum indicator ascends above 0 level on May 12, 2025
5/13/2025 - Tickeron - Stocks
Neurogene (NASDAQ:NGNE) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
5/13/2025 - MarketBeat
Deerfield Management Company L.P. Series C Makes New Investment in Neurogene Inc. (NASDAQ:NGNE)
5/10/2025 - MarketBeat
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates NGNE ...
5/9/2025 - GuruFocus
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
5/9/2025 - GuruFocus
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
5/9/2025 - Business Wire
Neurogene (NGNE, $15) price moved above its 50-day Moving Average on May 08, 2025
5/9/2025 - Tickeron - Stocks
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/8/2025 - GuruFocus
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/8/2025 - Business Wire
DAFNA Capital Management LLC Purchases 43,725 Shares of Neurogene Inc. (NASDAQ:NGNE)
5/8/2025 - Ticker Report
Casdin Capital LLC Grows Stake in Neurogene Inc. (NASDAQ:NGNE)
5/8/2025 - MarketBeat
Price T Rowe Associates Inc. MD Invests $2.82 Million in Neurogene Inc. (NASDAQ:NGNE)
5/8/2025 - MarketBeat
Neurogene (NGNE, $13.05) entered Downtrend as Momentum indicator drops below 0 level on May 06, 2025
5/7/2025 - Tickeron - Stocks
Neurogene (NGNE, $13.05) price exceeded its 50-day Moving Average on May 06, 2025
5/7/2025 - Tickeron - Stocks
Baker BROS. Advisors LP Boosts Holdings in Neurogene Inc. (NASDAQ:NGNE)
5/6/2025 - MarketBeat
H.C. Wainwright Remains a Buy on Neurogene (NGNE)
5/6/2025 - TipRanks Financial Blog
Neurogene (NGNE) Expected to Announce Earnings on Friday
5/4/2025 - MarketBeat
Samsara BioCapital LLC Acquires 449,337 Shares of Neurogene Inc. (NASDAQ:NGNE)
5/2/2025 - MarketBeat
Neurogene (NGNE, $15) price moved above its 50-day Moving Average on April 30, 2025
5/1/2025 - Tickeron - Stocks
Neurogene (NGNE, $13.03) price exceeded its 50-day Moving Average on April 29, 2025
4/30/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$925.00K
EBITDA (TTM)
-$86.56M
EBIT (TTM)
-$89.75M
Net Income (TTM)
-$80.87M
Balance Sheet
Total Assets (Q)
$315.30M
Total Debt (Q)
$11.71M
Total Liabilities (Q)
$23.51M
Book Value Per Share (Q)
$19.54
Cash Flow
Cash from Operations (TTM)
-$69.73M
Cash from Investing (TTM)
-$200.24M
Cash from Financing (TTM)
$190.60M
Net Change in Cash (TTM)
-$79.37M
Filings
Filing Date
Friday, May 9, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
--
7-Day Total Return
2.13%
30-Day Total Return
59.83%
60-Day Total Return
-11.06%
90-Day Total Return
-32.58%
Year to Date Total Return
-32.58%
1-Year Total Return
-51.09%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 08, 2025 - $6.88
52-week High
Nov 11, 2024 - $74.49
Valuation
Market Cap
$221.20M - Micro Cap
Enterprise Value
-$59.69M
Price/Sales (TTM)
352.50
Price/Book (Q)
0.79
Dividends and Shares
Shares Outstanding
21.00M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.neurogene.com
Phone Number
855 508 3568
Address
535 W 24th Street
New York, NY 10011
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an... more
NASDAQ 05/14/2025 11:11AM Eastern Quotes delayed